The total return over the past 12 months is +60.94% vs. +16.94% for the S&P 500. So far it's up -5.78% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +60.94% | +35.10% | (10.28%) | N/A | N/A | N/A |
| Total Return CAGR | +60.94% | +35.10% | (10.28%) | N/A | N/A | N/A |
| Revenue CAGR | +3.18% | +28.71% | +35.55% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | (101.42%) | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (31.77%) | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Castle Biosciences, Inc. (CSTL)
| Year | Start price | End price | CSTL Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $38.90 | $36.65 | (5.78%) | +14.51% | (20.29%) |
| 2025 | $26.65 | $38.90 | +45.97% | +17.72% | +28.25% |
| 2024 | $21.58 | $26.65 | +23.49% | +24.89% | (1.40%) |
| 2023 | $23.54 | $21.58 | (8.33%) | +26.19% | (34.52%) |
| 2022 | $42.87 | $23.54 | (45.09%) | (18.17%) | (26.92%) |
| 2021 | $67.15 | $42.87 | (36.16%) | +28.74% | (64.90%) |
| 2020 | $34.37 | $67.15 | +95.37% | +18.37% | +77.00% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
